Selective ablation of the ligament of Marshall reduces ischemia and reperfusion-induced ventricular arrhythmias

PloS One
Ruisong MaHong Jiang

Abstract

Cardiac sympathetic tone overdrive is a key mechanism of arrhythmia. Cardiac sympathetic nerves denervation, such as LSG ablation or renal sympathetic denervation, suppressed both the prevalence of VAs and the incidence of SCD. Accumulating evidence demonstrates the ligament of Marshall (LOM) is a key component of the sympathetic conduit between the left stellate ganglion (LSG) and the ventricles. The present study aimed to investigate the roles of the distal segment of LOM (LOMLSPV) denervation in ischemia and reperfusion (IR)-induced VAs, and compared that LSG denervation. Thirty-three canines were randomly divided into group 1 (IR group, n = 11), group 2 (LOMLSPV Denervation + IR, n = 9), and group 3 (LSG Denervation + IR, n = 13). Hematoxylin-Eosin (HE) and Immunohistochemistry staining revealed that LOMLSPV contained bundles of sympathetic but not parasympathetic nerves. IR increased the cardiac sympathetic tone [serum concentrations of noradrenaline (NE) and epinephrine (E)] and induced the prevalence of VAs [ventricular premature beat (VPB), salvo of VPB, ventricular tachycardia (VT), VT duration (VTD) and ventricular fibrillation (VF)]. Both LOMLSPV denervation and LSG denervation could reduce the cardiac sympathetic to...Continue Reading

References

Oct 1, 1978·Environmental Health Perspectives·E W Van Stee
Oct 12, 2000·Journal of the American College of Cardiology·D T KimM C Fishbein
Jul 14, 2006·Journal of Cardiovascular Electrophysiology·Mutsuki MakinoHidekazu Ota
Dec 7, 2007·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Shengmei ZhouLan S Chen
Apr 12, 2013·Journal of Cardiovascular Electrophysiology·Justin HayaseDavid E Krummen
Feb 14, 2014·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·L R A Olde NordkampA A M Wilde
Mar 15, 2014·Circulation Research·Mark J Shen, Douglas P Zipes
Apr 30, 2014·Revista Española De Cardiología·Emilio García-MoránCarolina Hernández-Luis
Sep 22, 2015·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Bing HuangHong Jiang
Jul 19, 2016·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Ye ZhaoThomas H Everett

❮ Previous
Next ❯

Citations

Mar 28, 2019·Frontiers in Physiology·Yanqiu LaiHong Jiang

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.